Review
Copyright ©The Author(s) 2019.
World J Stem Cells. Sep 26, 2019; 11(9): 650-665
Published online Sep 26, 2019. doi: 10.4252/wjsc.v11.i9.650
Table 1 Expandable hepatic cells induced from primary hepatocytes to date
Hepatocyte source(s)ChemicalsGrowth factor(s)Medium and supplementsExpansion potential
Yr
Passage countDoubling time
Mouse and RatA83-01, CHIR99021, Y-27632EGFDMEM/F12, HEPES, L-proline, ITS, dexamethasone, nicotinamide, ascorbic acid-2 phosphate, BSA, antibiotic/ antimycoticRat: >10; Mouse: >20Rat: 14.7 ± 1.1 h2017[62]
MouseA83-01, CHIR99021, Y-27632EGF, HGFDMEM/F12, N2 or ITS, S1P, LPA>3015-20 h2017[63]
Human (resected patient liver tissue, non-lesion)A83-01, CHIR99021EGF, HGFDMEM/F-12 (high glucose), FBS, nicotinamide, dexamethasone, ITS, penicillin/ streptomycin>1037.9-39.8 h2018[64]
Human (resected patient liver tissue, non-lesion)A83-01, CHIR99021, Y-27632EGF, HGFAdvanced DMEM/F-12, N2, B27, sodium pyruvate, ascorbic acid, S1P, LPA>1024.7 ± 1.4 h2018[67]
Human (normal, cryopreserved)A83-01, Y-27632EGF, FGF10, HGF, Wnt3aAdvanced DMEM/F-12, FBS, N2, B27 (minus vitamin A), N-acetylcysteine, nicotinamide, [Leu15]-gastrin I, penicillin/ streptomycin,4 (normoxia); 8 (hypoxia)2018[68]
Human (normal, freshly isolated and cryopreserved)A83-01, CHIR99021, Y-27632EGF, FGF7, FGF10, HGF, TGFaAdvanced DMEM/F-12, HEPES, B27 (minus vitamin A), R-spodin1 conditioned medium, N-acetylcysteine, nicotinamide, gastrin, GlutaMAX, penicillin/ streptomycin,Fetal hepatocytes: >165-7 d2018[70]
Table 2 The specificity and commonality of chemicals in direct lineage conversion
CompoundsFunctionTarget germ layer and cell types
Ref.
Ectoderm: Neural stem/ progenitor cell, neuronMesoderm: CardiomyocyteEndoderm/ extraembryonic endoderm: Endoderm progenitor cell, XENs
A83-01TGF-βRI (ALK4/5/7) inhibitor++[42,43,51,53]
AM580RAR agonist+[25,54]
AS8351KDM5B inhibitor+[53]
Bay K 8644Ca2+ channel activator+[51]
BIX01294Histone methyltransferase inhibitor++[42,53]
CHIR99021GSK3 inhibitor+++[25,41-46,50,51,53-55,78]
DMH1BMP inhibitor+[46]
EPZ004777DOT1L inhibitor+[25,54]
ForskolincAMP activator+++[25,44-46,50,51,54,55,78]
GO6983PKC inhibitor+[44]
Hh-Ag1.5Smo agonist+[43]
I-BET151BET bromodomain inhibitor+[78]
ISX9Neurogenic agent+[78]
JNJ10198409PDGF-RTK inhibitor+[53]
LDN193189BMP type I receptor (ALK2/3) inhibitor+[43,45]
OAC2Oct4 activator+[53]
Parnate (Tranylcypromine)LSD1/MAO inhibitor+++[25,43,50,54]
PD0325901MEK inhibitor+[42,45]
RepSox (616452)TGF-βRI (ALK5) inhibitor+++[25,41,44,46,50,54,55]
RG108DNA methyltransferase inhibitor+[42,43]
SB431542TGF-βRI (ALK4/7) inhibitor+[45,78]
SC1ERK1/RasGAP inhibitor+[51,53]
SMER28Autophagy modulator+[43]
SP600125JNK inhibitor+[44,46]
SU16FPDGFRβ inhibitor+[53]
TTNPBRAR agonist++[50,55]
VPAHistone deacetylase inhibitor+++[25,41,42,44,46,50,54]
Y‑27632ROCK inhibitor+++[44,46,53-55]
Table 3 Advantages and disadvantages of different strategies for functional cell induction
StrategyInduction efficiencyReproducibi-lity/stabilityTarget specificityCellular functionIn vivo engraftmentSafetyScaling upCostRef.
TF-mediated pluripotent reprogramming followed by differentia-tionModerateHighly reproducible/ stableHighImmatureLowGenomic integration; tumorigenesis riskExpandable before differentia-tionVery high[11,97-99]
TF-mediated direct lineage conversionFast and efficientReproducible/stableHighDeficientLowGenomic integrationExpandable in progenitorsHigh[100-103]
Chemical-mediated pluripotent reprogramming followed by differentia-tionControversialPoorly reproducible/ unstableLowNot clearNot clearIntegration-freeNot clearLow[24,25,29,31]
Chemical-mediated direct lineage conversionLowReproducible/ unstableLowDeficientLowIntegration-freeExpandable in progenitorsVery low[18,77,104,105]
Chemical-mediated direct lineage expansionFast and efficientReproducible/ unstableLowClose to primaryHighIntegration freeExpandable in rodents/ Limited in humansVery low[62,64,67,68]